-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Duchenne muscular dystrophy (DMD) is the most common type of progressive muscular dystrophy, with progressive and lethal features
Duchenne muscular dystrophy (DMD) is caused by the absence or loss of function of dystrophin
The gene encoding dystrophin is located at Xp21.
Japanese pharmaceutical company Astellas has disclosed that it will discontinue its AT702, AT751 and AT753 gene therapy programs for Duchenne muscular dystrophy (DMD) based on recent preclinical study data
The company's gene therapy approach for DMD uses an AAV vector encoding a modified U7 snRNA to deliver an antisense sequence designed to induce cells to skip the erroneous or misplaced genetic code in the dystrophin gene, thereby restoring functional dystrophin Production of atrophin
The company's gene therapy approach for DMD uses an AAV vector encoding a modified U7 snRNA to deliver an antisense sequence designed to induce cells to skip the erroneous or misplaced genetic code in the dystrophin gene, thereby restoring functional dystrophin Production of atrophin
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5554133 https://firstwordpharma.
com/story/5554133
Leave a comment here